Rocket Pharmaceuticals received a regenerative medicine advanced therapy designation from the Food and Drug Administration for its heart disease treatment.

Acquisition provides I-Mab with upstream rights to CLDN18.2 parental antibody for use in bispecific and multi-specific applications <li ...

So far, eight children have been born, all reportedly healthy, thanks to the long-term efforts of scientists and doctors in ...

Traditionally, drug discovery relied heavily on trial and error, with long timelines and high costs. The introduction of ...